← ANALYST RATINGS · TIPRANKS
Belite Bio, Inc. ADR (BLTE): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months · top analysts only12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $269, the highest $303, the lowest $234. The average is +88.4% from the last price of $143.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $204 → $151−26.0% | Hold | +5.8% | Reiterated | 17.10.26on TipRanks 01:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $206 → $153−25.7% | Hold | +7.2% | Reiterated | 17.10.26on TipRanks 01:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $204 → $151−26.0% | Hold | +5.8% | Reiterated | 17.10.26on TipRanks 01:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $200 → $148−26.0% | Hold | +3.7% | Reiterated | 17.10.26on TipRanks 01:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $206 → $153−25.7% | Hold | +7.2% | Reiterated | 17.10.26on TipRanks 01:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $199 → $147−26.1% | Hold | +3.0% | Reiterated | 17.10.26on TipRanks 01:05 | — | |
| Yi Chen★★★★★★★★★★#10518 · hits 41% · avg −1.0% | H.C. Wainwright | $245 | Buy | +71.6% | Reiterated | 15.10.26on TipRanks 07:14 | −0.4%next day −5.3% | ↗ |
| Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% | Mizuho Securities | $220 → $234+6.4% | Buy | +63.9% | Reiterated | 09.09.26on TipRanks 07:10 | −4.6%next day −3.8% · 5 days −6.5% | ↗ |
| Whitney Ijem★★★★★★★★★★#537 · hits 48% · avg +20.2% | Canaccord Genuity | $303 | Buy | +112.2% | Initiated | 04.09.26on TipRanks 05:25 | +13.5%next day +0.2% · 5 days −9.4% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $200 | Buy | +40.1% | Reiterated | 02.09.26on TipRanks 22:05 | +5.4%next day +13.5% · 5 days +2.7% | ↗ |
| Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% | Morgan Stanley | $201 → $206+2.5% | Buy | +44.3% | Reiterated | 17.08.26on TipRanks Aug 14 08:35 | −1.9%next day +0.7% · 5 days +0.3% | ↗ |
| Michael Okunewitch★★★★★★★★★★#11525 · hits 36% · avg −3.3% | Maxim Group | $200 | Buy | +40.1% | Reiterated | 14.08.26on TipRanks Aug 15 14:25 | −1.9%next day +0.7% · 5 days +0.3% | ↗ |
| Steven Seedhouse★★★★★★★★★★#1374 · hits 43% · avg +10.3% | Cantor Fitzgerald | $266 → $270+1.5% | Buy | +89.1% | Reiterated | 14.08.26on TipRanks Aug 12 10:35 | +0.5%next day −7.8% · 5 days −5.4% | ↗ |
| Bruce Jackson★★★★★★★★★★#12272 · hits 38% · avg −9.8% | Benchmark Co. | $187 → $217+16.0% | Buy | +52.0% | Reiterated | 03.03.26on TipRanks 08:30 | −4.6%next day +5.2% · 5 days +4.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Belite Bio, Inc. ADR
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 2 | 2 |
| Buy | 3 | 1 | 1 | 3 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 17.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.79 (from $-1.16 to $-0.52). Last quarter: $-0.70.
Best top-analyst consensus in the sector · Healthcare
About Belite Bio, Inc. ADR
- CEO: Yu-Hsin Lin
- Employees: 41
- 12750 High Bluff Drive, San Diego, CA, 92130, US
- belitebio.com
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Data from the stock’s TipRanks forecast page, read 51 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗